167 related articles for article (PubMed ID: 38439632)
1.
Alzahrani SO; McRobbie G; Khan A; D'huys T; Van Loy T; Walker AN; Renard I; Hubin TJ; Schols D; Burke BP; Archibald SJ
Dalton Trans; 2024 Mar; 53(12):5616-5623. PubMed ID: 38439632
[TBL] [Abstract][Full Text] [Related]
2.
Burke BP; Miranda CS; Lee RE; Renard I; Nigam S; Clemente GS; D'Huys T; Ruest T; Domarkas J; Thompson JA; Hubin TJ; Schols D; Cawthorne CJ; Archibald SJ
J Nucl Med; 2020 Jan; 61(1):123-128. PubMed ID: 31201250
[TBL] [Abstract][Full Text] [Related]
3. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.
Labrosse B; Brelot A; Heveker N; Sol N; Schols D; De Clercq E; Alizon M
J Virol; 1998 Aug; 72(8):6381-8. PubMed ID: 9658078
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
5. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
6. Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor.
Liang X; Parkinson JA; Weishäupl M; Gould RO; Paisey SJ; Park HS; Hunter TM; Blindauer CA; Parsons S; Sadler PJ
J Am Chem Soc; 2002 Aug; 124(31):9105-12. PubMed ID: 12149014
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.
Misra AC; Luker KE; Durmaz H; Luker GD; Lahann J
Biomacromolecules; 2015 Aug; 16(8):2412-7. PubMed ID: 26154069
[TBL] [Abstract][Full Text] [Related]
8. Blockade of hypoxia-induced CXCR4 with AMD3100 inhibits production of OA-associated catabolic mediators IL-1β and MMP-13.
Li P; Deng J; Wei X; Jayasuriya CT; Zhou J; Chen Q; Zhang J; Wei L; Wei F
Mol Med Rep; 2016 Aug; 14(2):1475-82. PubMed ID: 27356492
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
10. Selective recognition of configurational substates of zinc cyclam by carboxylates: implications for the design and mechanism of action of anti-HIV agents.
Liang X; Weishäupl M; Parkinson JA; Parsons S; McGregor PA; Sadler PJ
Chemistry; 2003 Oct; 9(19):4709-17. PubMed ID: 14566877
[TBL] [Abstract][Full Text] [Related]
11. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
[TBL] [Abstract][Full Text] [Related]
12. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of CXCR4 synergizes with LL-37 in the metastasis of breast cancer cells.
Pan WL; Wang Y; Hao Y; Wong JH; Chan WC; Wan DC; Ng TB
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3837-3846. PubMed ID: 30251699
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor.
Rosenkilde MM; Gerlach LO; Jakobsen JS; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2004 Jan; 279(4):3033-41. PubMed ID: 14585837
[TBL] [Abstract][Full Text] [Related]
16. Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B-adrenergic receptors controls α1-adrenergic receptor function.
Tripathi A; Vana PG; Chavan TS; Brueggemann LI; Byron KL; Tarasova NI; Volkman BF; Gaponenko V; Majetschak M
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1659-68. PubMed ID: 25775528
[TBL] [Abstract][Full Text] [Related]
17. The Impact of CXCR4 Blockade on the Survival of Rat Brain Cortical Neurons.
Merino JJ; Garcimartín A; López-Oliva ME; Benedí J; González MP
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916896
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of a CXCR4-targeting bis(cyclam) lipid.
Peters AD; McCallion C; Booth A; Adams JA; Rees-Unwin K; Pluen A; Burthem J; Webb SJ
Org Biomol Chem; 2018 Sep; 16(35):6479-6490. PubMed ID: 30155533
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
